The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Size Is Forecasted For The Oncology Molecular Diagnostics Market By 2030 Based On Its 2026 Value?
The oncology molecular diagnostics market has seen considerable expansion in recent years. Its valuation is predicted to rise from $5.65 billion in 2025 to $6.34 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.2%. This market’s historical growth can be attributed to a higher incidence of cancer, the adoption of PCR and sequencing techniques, increased funding for oncology research, the broader reach of hospital diagnostic facilities, and regulatory clearances for molecular tests.
The oncology molecular diagnostics market is anticipated to experience substantial expansion over the next few years. It is projected to reach a value of $10.13 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.4%. This anticipated growth during the forecast period is attributable to factors such as the increasing adoption of precision oncology, advancements in liquid biopsy, the growing demand for personalized treatments, AI-driven data interpretation, and the penetration into emerging markets. Prominent trends observed in this period include the expansion of companion diagnostics, the rising utilization of liquid biopsy, the broader implementation of biomarker-based testing, an increase in cancer screening programs, and the persistent demand for early and accurate cancer detection.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3457&type=smp
What Important Drivers Are Powering The Oncology Molecular Diagnostics Market Growth?
The escalating need for personalized medicine is projected to drive the expansion of the oncology molecular diagnostics market in the coming years. Personalized medicine denotes an innovative medical and healthcare strategy that customizes medical choices, procedures, interventions, and drug therapies for each patient. Oncology molecular diagnostics are vital for cancer patients within the realm of personalized medicine because they deliver tailored treatment programs, optimized medication choices, and more exact, potent, and individualized treatment strategies, leading to improved patient results and a better quality of life. For instance, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Thus, the rising demand for personalized medicine is propelling the growth of the oncology molecular diagnostics market.
What Segment Types Are Included In The Oncology Molecular Diagnostics Market Analysis?
The oncology molecular diagnostics market covered in this report is segmented –
1) By Product: Instruments, Reagents, Other Products
2) By Technology: Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips And Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA), Other Technologies
3) By End User: Hospitals, Diagnostic Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Instruments: Polymerase Chain Reaction (PCR) Machines, Sequencers, Microarray Platforms, Fluorescence In Situ Hybridization (FISH) Instruments
2) By Reagents: DNA And RNA Extraction Kits, PCR Reagents And Kits, NGS Library Preparation Kits, Diagnostic Assay Reagents
3) By Other Products: Software For Data Analysis And Interpretation, Quality Control And Calibration Products, Consumables, For Molecular Testing, Biomarkers For Oncology Testing
Which Trends Are Supporting The Evolution Of The Oncology Molecular Diagnostics Market?
Leading companies in the oncology molecular diagnostics market are prioritizing the advancement of genomics technologies, including next-generation cancer genome sequencing, computational analytics, and innovative tumor modeling, to enhance early cancer detection, mutation identification, and personalized treatment strategies. These developments boost diagnostic precision, decrease turnaround times, and cater to the increasing need for localized, highly accurate molecular testing. Illustratively, in May 2024, OncoHelix-CoLab, a Canada-based precision oncology provider focused on genomic and immunologic profiling, advanced molecular diagnostics, and immune-profile testing, launched a state-of-the-art laboratory at Burjeel Medical City in the UAE. Developed through a collaboration between Burjeel Holdings and OncoHelix, this facility strengthens regional diagnostic capabilities by enabling complex molecular and immunology tests to be conducted locally rather than sent abroad. Its specialized offerings include advanced assays for multiple cancers, such as prostate cancer, supported through partnerships like its collaboration with Nanostics for the ClarityDX Prostate test.
Which Firms Are Competing In The Oncology Molecular Diagnostics Market?
Major companies operating in the oncology molecular diagnostics market are F. Hoffmann-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare AG, Becton Dickinson and Company, Agilent Technologies Inc., HTG Molecular Diagnostics Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corp., Bio-Techne Corporation, OPKO Health Inc., Myriad Genetics Inc., Guardant Health AMEA, Veracyte Inc., Adaptive Biotechnologies Corp., Foundation Medicine Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Genomic Health Inc.
Access The Complete Oncology Molecular Diagnostics Market Report:
Which Region Commands The Largest Share Of The Oncology Molecular Diagnostics Market?
North America was the largest region in the oncology molecular diagnostics market in 2025. Western Europe was the second largest region in the global oncology molecular diagnostics market report. The regions covered in the oncology molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Oncology Molecular Diagnostics Market Report for Deeper Competitive Insights
Browse Through More Reports Similar to the Global Oncology Molecular Diagnostics Market 2026, By The Business Research Company
Diagnostic Imaging Equipment Market Report 2026
https://www.thebusinessresearchcompany.com/report/diagnostic-imaging-equipment-global-market-report
Diagnostic And Monitoring Ophthalmic Devices And Equipment Market Report 2026
Microbiology Diagnostic Devices And Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model